Ignite Creation Date:
2025-12-26 @ 10:58 AM
Ignite Modification Date:
2026-01-13 @ 3:29 PM
Study NCT ID:
NCT00858806
Status:
COMPLETED
Last Update Posted:
2014-12-03
First Post:
2009-03-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy
Sponsor:
Università degli Studi di Brescia
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2007-005102-42
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None